The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
John F. DiPersio
No relevant relationships to disclose
Harry Paul Erba
No relevant relationships to disclose
Richard A. Larson
No relevant relationships to disclose
Selina M. Luger
No relevant relationships to disclose
Kenneth Francis Mangan
No relevant relationships to disclose
Martin S. Tallman
No relevant relationships to disclose
Jeffrey Mark Brill
Employment or Leadership Position - Ascenta Therapeutics
Gregoire Vuagniaux
Employment or Leadership Position - Debiopharm Group
Elisabeth Rouits
Employment or Leadership Position - Debiopharm Group
Claudio Zanna
Employment or Leadership Position - Debiopharm Group
J. Mel Sorensen
Employment or Leadership Position - Ascenta Therapeutics